AstraZeneca to invest $3.5 billion in the United States
British-Swedish drugmaker AstraZeneca plans to invest $3.5 billion in the United States by the end of 2026 to expand the company's research and manufacturing footprint.
The investment includes a new R&D center in Cambridge, Massachusetts, a biologics manufacturing facility in Maryland, and expanded cell therapy production capabilities on the West and East Coasts and specialty products in Texas.
AstraZeneca CEO Pascal Soriot said: "Our multi-billion dollar investment reflects the attractiveness of the U.S. business environment and the quality of its talent and innovation. By expanding our R&D and manufacturing footprint, we aim to strengthen the development of cutting-edge therapies and support U.S. leadership in medical innovation."
AstraZeneca said the planned investments in the United States are part of its goal of achieving $80 billion in total revenue by 2030. AstraZeneca said the United States is its largest market, contributing 44% of its total revenue.
2026-09-09
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
AstraZeneca and CSPC Strengthen Biologics Manufacturing Partnership in China
-
AstraZeneca Pays Up to $1.5 Billion for Global Rights to Chinese Lung Cancer Drug
-
AstraZeneca’s Wainua Fails Phase III Heart Trial, Wiping Out About $27 Billion in Market Value
-
$15 Billion Invested in China: AstraZeneca Builds an “Innovation Hub” While Some Are Still Waiting for the Windfall
-
AstraZeneca to Invest $2 Billion in New U.S. Biologics Facilities
-
AstraZeneca to Invest $2.5 Billion to Establish Global Drug R&D Center in Beijing
-
Ascending to the Summit: AstraZeneca Crowned as the Most Competitive MNC in China
-
Restructuring at AstraZeneca China: Leadership Changes and New Business Division
-
Bristol Myers Squibb's Acquisition Spree: Will it Boost its Cancer Drug Portfolio?
-
Is AstraZeneca's Acquisition of Gracell Biotechnologies a Game-Changer for Cell Therapy and Expansion in China?
Recommend Reading
-
BASF and Clariant Exit Quietly! Behind Henkel’s High-Priced Acquisition, Why Did Former Allies Choose to “Let Go”?
-
BASF and Nihon Nohyaku Partner for Fruit Crop Protection in Japan
-
NHU and Sinopec Advance Liquid Methionine Project
-
Mitsubishi Gas Chemical Suspends Construction of MXDA Plant in the Netherlands
-
Symrise Opens New Production Unit in Granada to Ensure Safer Supply of Bio-Based Pentylene Glycol
-
This Week's Anhydrous Hydrogen Fluoride Market Prices Stabilize in China (9.15-9.19)
-
Both Supply and Demand Weak, Polyethylene Operates on the Weaker Side
-
This week, the market price center of propylene oxide in China has shifted upward (9.15-9.19)
-
Ethanol Market Remains at High Levels with Consolidation
-
This Week's Styrene Market Fluctuates and Rises (9.15-9.19) in China
- Hot Searches
- bulk sodium hyaluronate reseller
- bachem reta
- polyvinyl chloride price
- pure sodium chloride
- cromic acid
- alminium chloride
- formic acid powder
- buy kpv peptide
- tergitol 91-6
- hydroxypropyl methylcellulose
- sodium potassium mag sulfates 17.5 gram-3.13 gram-1.6 gram oral solution
- retatrutide for sale online usa